GSK to reimburse tuition fees for UK trainees
March 3, 2011Business Services, Research and Development, Sales and Marketing GSK, GlaxoSmithKline, UK science, careers, graduate, graduate recruitment
GlaxoSmithKline is set to reimburse UK university tuition fees paid by its trainees from 2012. Each year, GSK recruits between …
Forest’s COPD drug approved in US
March 3, 2011Sales and Marketing COPD, Daliresp, Daxas, Forest, Forest Laboratories, chronic obstructive pulmonary disease, roflumilast
Daliresp (roflumilast) has been approved by the FDA to treat severe chronic obstructive pulmonary disease. Forest Laboratories’ once-daily pill is …
RNA interference – still the great white hope?
March 3, 2011Manufacturing and Production, Research and Development RNA interference, rnai
The emerging field of RNA interference – also known as ‘gene silencing’ – is one of the most promising in …
NHS competition plans provide focus for dissent
March 3, 2011Health and Social Care Bill, NHS, NHS reforms
Confusion and controversy surround the government plans to introduce greater levels of competition into the NHS, with many stakeholder groups …
FDA knocks back Merck KGaA’s oral MS drug
March 2, 2011Sales and Marketing Cladribine, EMD Serono, FDA, MS, Merck KGaA, Movectro, multiple sclerosis, oral MS drugs
US authorities have turned down Merck KGaA’s new drug application for its oral relapsing-remitting multiple sclerosis treatment Movectro. The FDA …
UCB teams up with Harvard for CNS research
March 2, 2011Research and Development CNS, Harvard, UCB, academia, academic research, immunology
UCB has signed a new research collaboration with Harvard University that will focus on central nervous system and immunology therapies. …
Boehringer’s Kay O’Hagan moves to Brecon
March 2, 2011Manufacturing and Production, Research and Development Brecon, Kay O'Hagan, appointment, manufacturing and production, research and development
Kay O’Hagan has joined commercial packaging and clinical trials supply services company Brecon Pharmaceuticals as director of quality assurance and …
Avastin’s breast cancer use to continue in Europe
March 2, 2011Sales and Marketing CHMP, Cancer, European Commission, Roche, avastin, bevacizumab, breast cancer, docetaxel, paclitaxel
Roche’s Avastin will remain on the market as a treatment for breast cancer, but only in combination with paclitaxel, the …
GlaxoSmithKline seeks alliances with ‘academic superstars’
March 2, 2011Research and Development GSK, GlaxoSmithKline, Pentraxin Therapeutics, academia, al Free and University College Medical School, universities
GlaxoSmithKline has unveiled a partnership with a ‘superstar academic’, as part of a new strategy which it believes will help …
Daiichi Sankyo gains rights to potential blockbuster cancer drug
March 2, 2011Research and Development BRAF protein, Daiichi Sankyo, PLX4032, Plexxikon, melanoma, personalised medicine
Daiichi Sankyo has purchased US-based discovery firm Plexxikon for $805 million, gaining access to its potential blockbuster melanoma drug PLX4032. …
Samsung forges biosimilar venture with Quintiles
March 2, 2011Manufacturing and Production Quintiles, Samsung, biosimilar production, biosimilars, pharma production
South Korean electronics giant Samsung has formed a joint venture with Quintiles with the objective of breaking into the market …
Fujifilm buys into bio with Merck acquisitions
March 2, 2011Manufacturing and Production Biomanufacturing, Fujifilm, Merck, Merck & Co, Merck/MSD Biomanufacturing Network, contract manufacturing
Japanese photography and imaging company Fujifilm continued its diversification into other sectors with the acquisition of the Merck/MSD Biomanufacturing Network, …
Bayer goes for pharma growth
March 1, 2011Research and Development, Sales and Marketing 2010 pharma results, Bayer, Dr Jörg Reinhardt, Marijn Dekkers, Nexavar, VEGF Trap-Eye, Xarelto
While many of its larger peers in the pharma sector are rushing to diversify into consumer health and generics, Bayer, …
Pfizer drops 15 pipeline projects
March 1, 2011Research and Development Lyrica, Pfizer, Pfizer R&D, Pfizer product pipeline, Pfizer research, inotuzumab, pregabalin
Pfizer has again slimmed down its product pipeline as the US giant looks to cut R&D spending and sharpen its …
LEO Pharma Selects Veeva CRM for Pan-European Deployments
March 1, 2011Sales and Marketing veeva
BARCELONA, SPAIN — 1 March, 2011 – LEO Pharma, a leading global pharmaceutical company specialising in dermatology and critical care, …
Dutch government sells off vaccine facility
March 1, 2011Manufacturing and Production Bilthoven, Holland, NVI, Netherlands, Netherlands Vaccine Institute, vaccine manfacturing, vaccine production, vaccines
The Dutch government has put the manufacturing activities and capacity of the Netherlands Vaccine Institute in Bilthoven up for sale, …
Catalent sells off printed components business
March 1, 2011Manufacturing and Production Catalent, Clondalkin, pharma packaging, pharmaceutical packaging
Catalent Pharma Solutions has agreed to sell its printed components business to Dutch packaging giant Clondalkin, which has been steadily …
Nampak to leave Portsmouth for new facility
March 1, 2011Manufacturing and Production Nampak Healthcare, Portsmouth, Segensworth, pharma packaging, pharmaceutical carton facility
Nampak Healthcare plans to invest in a new manufacturing facility in Segensworth, UK, to overcome the limitations of its current …
Friedhelm Felten to head procurement at Merck
March 1, 2011Manufacturing and Production, Research and Development Friedhelm Felten, Merck KGaA, appointment, manufacturing and production, research and development
Merck KGaA has appointed Friedhelm Felten as its new head of corporate procurement with responsibility for the group’s global purchasing …
Forest depression candidate struggles against placebo
March 1, 2011Research and Development Forest, Forest Laboratories, Gedeon Richter, cariprazine, depression, major depressive disorder
An investigational antipsychotic drug being developed by Forest Laboratories and Budapest-based Gedeon Richter has failed to prove itself in phase …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
